Truist Financial Upgrades Mersana Therapeutics (NASDAQ:MRSN) to Buy

Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) was upgraded by equities researchers at Truist Financial from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Benzinga reports. The firm presently has a $9.00 price objective on the stock. Truist Financial’s price target would indicate a potential upside of 85.57% […]

Related Keywords

Hong Kong ,Robertw Baird ,Anna Protopapas ,Brian Deschuytner ,Merck Kga ,Sphera Funds Management ,Y Intercept Hong Kong Ltd ,Citigroup ,Janssen Biotech Inc ,Mersana Therapeutics Inc ,Asana Biosciences ,Life Insurance Co ,Securities Exchange Commission ,Merck Kgaa ,Mersana Therapeutics ,Get Free Report ,Truist Financial ,Director Anna Protopapas ,Exchange Commission ,Funds Management ,Janssen Biotech ,Mersana Therapeutics Daily ,Nasdaq Mrsn ,Mrsn ,Medical ,Upgrade ,Truist Financial Co ,